October 26, 2014 5:00 AM ET

Biotechnology

Company Overview of OncoCyte Corporation

Company Overview

OncoCyte Corporation develops genetically modified stem cells for finding malignant tumors while carrying genes that cause the destruction of the cancer cells. It offers PanC-Dx bladder cancer markers to the performance of cystoscopy. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation operates as a subsidiary of BioTime, Inc.

1301 Harbor Bay Parkway

Alameda, CA 94502

United States

Founded in 2009

Phone:

510-521-3390

Fax:

510-521-3389

Key Executives for OncoCyte Corporation

Chief Executive Officer
Chief Executive Officer of Biotime
Age: 61
Chief Medical Officer
Compensation as of Fiscal Year 2014.

OncoCyte Corporation Key Developments

BioTime's Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute

BioTime Inc. and its subsidiary OncoCyte Corporation announced that OncoCyte's collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a blood-based lung cancer diagnostic test. OncoCyte previously entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer diagnostic products approximately one year ago. As part of the clinical study, over 600 blood samples were obtained from patients with a high-risk profile for development of lung cancer at six clinical sites. Enrollment was completed in June with all sites meeting or exceeding their collection goals. Wistar investigators are currently assessing gene expression patterns in blood cells of patients with malignant versus non-malignant lung disease. The analysis of patient data from this study should be completed by the end of October with submission of the study results for publication in a peer-reviewed journal to follow. The performance of markers tested in the study in determining the presence or the progression of disease in various categories of patients may determine the specific nature of the lung cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue. As part of the Sponsored Research Agreement, OncoCyte has an option to exclusively license any inventions, discoveries or technology developed by Wistar, or by OncoCyte using Wistar technology, in the course of the collaborative research and anticipates exercising this exclusive option if final results of the study are positive.

OncoCyte Corporation and Abcodia Ltd. Announces Collaboration Focused on the Development of OncoCyte’s blood-based PanC-Dx™ Test for Early Detection of Breast Cancer

On September 15, 2014, OncoCyte Corporation and Abcodia Ltd. announced their collaboration focused on the development of OncoCyte's blood-based PanC-Dx test for early detection of breast cancer. The collaboration will begin with an initial study to be completed by the end of 2014. Under the terms of the current agreement, OncoCyte will test the performance of its proprietary PanC-Dx cancer markers in detecting breast cancer in a set of patient samples selected from the biobank by Abcodia. If the outcome of this initial study is promising, future studies could proceed and expand into the use of a larger cohort to assess OncoCyte's PanC-Dx cancer markers in a case-controlled longitudinal design. The performance of the test in detecting the absence, presence, and development of early breast cancer will be considered in determining the intended use for PanC-Dx and the regulatory approval pathway that OncoCyte will pursue. As part of the initial collaboration, OncoCyte retains all rights to develop and market its proprietary breast cancer diagnostic products. The collaboration with Abcodia represents an expansion of OncoCyte's breast cancer clinical development program, which began early in 2014 with the initiation of an OncoCyte-sponsored 600-patient study at Scottsdale Medical Imaging Laboratories (SMIL) in Scottsdale, Arizona. Data from both studies will be used to support an initial use of the breast cancer diagnostic test by radiologists to aid in determining the malignancy potential of suspicious mammography findings, and by oncologists as a tool for recurrence surveillance in breast-cancer survivors. OncoCyte expects analysis of data from the SMIL cohort should be also completed by the end of 2014.

OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial

BioTime Inc. and its subsidiary OncoCyte Corporation announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(TM) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months. The goal of the current clinical trial is to compare the performance of OncoCyte's proprietary PanC-Dx(TM) bladder cancer markers to the performance of cystoscopy. Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer. Cystoscopy and biopsy results will be compared with the results of OncoCyte's proprietary diagnostic test panel in determining the overall performance of the PanC-Dx(TM) markers. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers discovered by OncoCyte scientists through an analysis of broad gene expression patterns in numerous cancer types. The performance of the test in detecting the absence, presence, or progression of urothelial carcinoma in patients will determine the specific nature of the bladder cancer diagnostic to be developed and the regulatory approval pathway that OncoCyte will pursue.

Similar Private Companies By Industry

Company Name Region
Aramed, Inc. United States
Asklepios BioPharmaceutical, Inc. United States
Envera LLC United States
CPEX Pharmaceuticals, Inc. United States
Northwest Plant Breeding Company United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OncoCyte Corporation, please visit www.oncocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.